Catalog product

45 orphan drugs included in China’s national medical insurance catalog

To date, 45 types of orphan drugs have been included in China’s national medical insurance catalog as the country steps up efforts to make drugs more affordable for patients with rare diseases.

These orphan drugs are used in the treatment of 26 rare diseases, according to data released at the ongoing 2022 China Rare Disease Conference in Beijing.

Since 2018, 19 new orphan drugs have been added to the national medical insurance catalog, with an average price reduction of 52.6 percent, said Huang Huabo, an official with the National Health Care Security Administration. , during the conference.

There are more than 20 million patients with various types of rare diseases in China, with the number increasing by more than 200,000 a year, according to the data.

These patients have received increasing attention from society in recent years, with Chinese authorities devoting great energy to supporting the prevention and treatment of rare diseases, strengthening research and development (R&D) and the supply of related drugs, and improve the medical insurance system.

So far, more than 60 kinds of orphan drugs have been approved for market entry, said Huang Guo, deputy director of the National Medical Products Administration.

Rare diseases pose serious public health problems worldwide. According to Qiao Jie, Academician of the Chinese Academy of Engineering, more than 7,000 rare diseases have been discovered worldwide, of which about 80% are hereditary.

For patients with rare diseases, access to medicines is the top priority. China has taken a series of measures, such as establishing a monitoring mechanism for orphan drug supply, improving orphan drug R&D and industrialization, and supporting medical Chinese tradition to play a role in this regard, in order to ensure the availability of orphan drugs.